These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8478140)

  • 1. Abrogation of tumor-inhibitory MRC-OX8+ (CD8+) effector T-cell generation in rats by selective depletion of neutrophils in vivo using a monoclonal antibody.
    Tanaka E; Sendo F
    Int J Cancer; 1993 Apr; 54(1):131-6. PubMed ID: 8478140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of the immune response to transplanted tumors in rats by selective depletion of neutrophils in vivo using a monoclonal antibody: abrogation of specific transplantation resistance to chemical carcinogen-induced syngeneic tumors by selective depletion of neutrophils in vivo.
    Midorikawa Y; Yamashita T; Sendo F
    Cancer Res; 1990 Oct; 50(19):6243-7. PubMed ID: 2119251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular requirements for tumor-specific immunity elicited by heat shock proteins: tumor rejection antigen gp96 primes CD8+ T cells in vivo.
    Udono H; Levey DL; Srivastava PK
    Proc Natl Acad Sci U S A; 1994 Apr; 91(8):3077-81. PubMed ID: 7909157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells.
    Yoshizawa H; Chang AE; Shu SY
    Cancer Res; 1992 Mar; 52(5):1129-36. PubMed ID: 1531321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of in vivo immune response by selective depletion of neutrophils using a monoclonal antibody, RP-3. I. Inhibition by RP-3 treatment of the priming and effector phases of delayed type hypersensitivity to sheep red blood cells in rats.
    Kudo C; Yamashita T; Araki A; Terashita M; Watanabe T; Atsumi M; Tamura M; Sendo F
    J Immunol; 1993 May; 150(9):3728-38. PubMed ID: 8473729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of IL-8-induced W3/25+ (CD4+) T lymphocyte recruitment into subcutaneous tissues of rats by selective depletion of in vivo neutrophils with a monoclonal antibody.
    Kudo C; Araki A; Matsushima K; Sendo F
    J Immunol; 1991 Oct; 147(7):2196-201. PubMed ID: 1918956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenotype analyses and cellular mechanisms of the pre-effector T-lymphocyte response to a progressive syngeneic murine sarcoma.
    Sakai K; Chang AE; Shu SY
    Cancer Res; 1990 Jul; 50(14):4371-6. PubMed ID: 2114215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.
    Ward BA; Shu S; Chou T; Perry-Lalley D; Chang AE
    J Immunol; 1988 Aug; 141(3):1047-53. PubMed ID: 3260908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of in vivo immune response by selective depletion of neutrophils using a monoclonal antibody, RP-3. II. Inhibition by RP-3 treatment of mononuclear leukocyte recruitment in delayed-type hypersensitivity to sheep red blood cells in rats.
    Kudo C; Yamashita T; Terashita M; Sendo F
    J Immunol; 1993 May; 150(9):3739-46. PubMed ID: 8473730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD8+ cell activation to a major mastocytoma rejection antigen, P815AB: requirement for tum- or helper peptides in priming for skin test reactivity to a P815AB-related peptide.
    Grohmann U; Bianchi R; Fioretti MC; Fallarino F; Binaglia L; Uyttenhove C; Van Pel A; Boon T; Puccetti P
    Eur J Immunol; 1995 Oct; 25(10):2797-802. PubMed ID: 7589074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Helper T cells against tumor-associated antigens (TAA): preferential induction of helper T cell activities involved in anti-TAA cytotoxic T lymphocyte and antibody responses.
    Fujiwara H; Yoshioka T; Shima J; Kosugi A; Itoh K; Hamaoka T
    J Immunol; 1986 Apr; 136(7):2715-9. PubMed ID: 3005417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of autologous tumor-specific cytotoxic T cells in patients with liver cancer. Characterizations and clinical utilization.
    Aruga A; Yamauchi K; Takasaki K; Furukawa T; Hanyu F
    Int J Cancer; 1991 Aug; 49(1):19-24. PubMed ID: 1678733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-cell-mediated antitumor immune response induced by oncofetal antigens.
    Gautam S; Deodhar SD
    J Natl Cancer Inst; 1981 Oct; 67(4):939-45. PubMed ID: 6974275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive immunotherapy of advanced tumors with CD62 L-selectin(low) tumor-sensitized T lymphocytes following ex vivo hyperexpansion.
    Wang LX; Chen BG; Plautz GE
    J Immunol; 2002 Sep; 169(6):3314-20. PubMed ID: 12218152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cell-surface epitope associated with liver-preferential metastasis detected by the new monoclonal antibody 3H4 in the murine tumor model ER 15-P.
    Wulf GG; Edel G; Deneke B; Gottschalk U; Hiddemann W; Wörmann B
    J Cancer Res Clin Oncol; 1996; 122(8):476-82. PubMed ID: 8698747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of host antigen receptor-bearing and antigen receptor-negative cells in immune response to rat adenocarcinoma 13762.
    Frey AB
    J Immunol; 1996 May; 156(10):3841-9. PubMed ID: 8621922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonspecific inhibition of tumor growth in vivo by admixed allogeneic tumor-sensitized lymphoid cells and identical inactivated allogeneic tumor cells.
    Sendo F; Nakayama M; Gotohda E; Kobayashi
    J Immunol; 1976 Oct; 117(4):1340-5. PubMed ID: 61998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of Ia+ reticulum cell sarcoma (RCS) growth in syngeneic SJL/J mice. I. Inhibition of tumor growth by passive administration of L3T4 monoclonal antibody before or after tumor inoculation.
    Ohnishi K; Bonavida B
    J Immunol; 1987 Jun; 138(12):4524-9. PubMed ID: 2953807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells.
    Shu S; Krinock RA; Matsumura T; Sussman JJ; Fox BA; Chang AE; Terman DS
    J Immunol; 1994 Feb; 152(3):1277-88. PubMed ID: 8301131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular interactions and the role of interleukin 2 in the expression and induction of immunity against a syngeneic murine sarcoma.
    Chou T; Shu S
    J Immunol; 1987 Sep; 139(6):2103-9. PubMed ID: 2957448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.